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WHITE MATTER LESIONS IN FTLD: DISTINCT
PHENOTYPES CHARACTERIZE GRN AND
C9ORF72 MUTATIONS
Frontotemporal lobar degeneration (FTLD) has a
high frequency of genetic forms; the 2 most common
are GRN (progranulin) and C9ORF72 mutations.
Recently, our group reported extensive white matter
(WM) lesions in 4 patients with FTLD caused by
GRN mutation, in the absence of noteworthy cardi-
ovascular risk factors,1 in line with other studies in
GRN mutation carriers.2,3 Here we compared the
characteristics of frontal WM lesions in patients with
behavioral variant of FTLD (bv-FTLD) caused by
GRN and C9ORF72 mutations.
Methods. Patients. We retrospectively collected clin-
ical and MRI data from 28 patients with a diagnosis
of bv-FTLD based on the Rascovsky criteria,4 includ-
ing 11 GRN mutation carriers and 17 C9ORF72
mutation carriers. One patient with multiple cardio-
vascular risk factors was excluded from this study; all
other patients had no cardiovascular risk factors apart
from sex, age, or treated and well-controlled hyper-
tension. Age at onset was determined as the time of
symptom appearance reported by the closest relative
of the patient. A group of 11 age-matched healthy
individuals were used as controls. Two GRN patients
have been reported in a previous publication.1 This
retrospective study was approved by our institutional
review board. Informed consent was obtained accord-
ing to the French legislation for clinical genetic
studies.
MRI. All patients had a brain MRI including fluid-
attenuated inversion recovery (FLAIR) sequence
(1.5T/3T, echo time .100 ms, slice thickness
#5 mm). One neuroradiologist (F.A.) assessed the
severity of left and right frontal atrophy using the
Kipps-Davis scale for frontal atrophy.5 Three neuro-
radiologists (F.A., S.S., and A. Bertrand) and 1 neu-
rologist (P.C.) characterized the severity of WM
lesions on FLAIR images in the left and right frontal
lobes using an ad hoc 3-level visual score (figure). All
readers were blinded to clinical and genetic data.
Statistical analysis was performed using GraphPad
Prism 5.0 (San Diego, CA). Interrater agreements
were assessed using the weighted k test. Comparisons
of sex and symptoms between the 3 groups were
assessed using the x2 test; other comparisons were
assessed using the Kruskal-Wallis test and Dunn post
hoc test (when comparing 3 groups) or the Mann-
Whitney test (when comparing 2 groups).
Results. No significant difference was observed
between groups regarding sex, age at onset, age at
MRI, disease duration, and associated amyotrophic lat-
eral sclerosis symptoms (table e-1 at Neurology.org/ng).
Interrater agreement between the 4 readers for the
characterization of WM lesions was moderate to very
strong (k 5 0.536–0.805, median 0.74).
Frontal WM lesions were different between the 3
groups (p 5 0.007 for the right side and p , 0.0001
for the left side, Kruskal-Wallis test). The grade of
WM lesions was higher on both sides in the GRN
group than in the control group and the C9ORF72
group (Dunn post hoc test) (figure).
In GRNmutation carriers, the presence of grade C
WM lesions on the left side was associated with a
higher degree of left frontal atrophy (p 5 0.003,
Mann-Whitney test) but not with longer disease
duration (p 5 0.082, Mann-Whitney test). No sig-
nificant result was observed for the right side, where
WM lesions were less frequent.
Discussion. Previous reports have shown that some
FTLD cases with GRN mutation present with
marked FLAIR hyperintensities in the WM.1–3,6 Here
we extended these findings by showing that these
WM lesions are frequent: 45% (5/11) of GRN muta-
tion carriers had extensive frontal WM lesions (grade
C) in the absence of noteworthy cardiovascular risk
factors. These WM lesions were atypical for common
cerebral small vessel disease because they extended
toward the subcortical WM (figure) and were associ-
ated with a higher degree of left frontal atrophy. They
were not associated with longer disease duration;
thus, they may be a consequence of a faster atrophy
process than in the other patients. Of note, the
patient excluded from the study because of cardiovas-
cular risk factors had only grade A WM lesions in the
frontal lobes.
It is interesting that both GRN and C9ORF72
mutation carriers are likely to have underlying FTLD-
TDP43 pathology. This suggests that gene effects can
exceed lesion effects in the phenotypical expression of
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FTLD. The progranulin protein is normally expressed
not only in neurons but also in activated microglia,
astrocytes, and oligodendroglia and plays a role in
inflammation.7 Histopathologic studies of the WM in
GRN mutation carriers have reported microglial activa-
tion in the areas of abnormal WM on MRI.2 These
results favor the hypothesis of a specific vulnerability of
the WM to granulin haploinsufficiency.
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Figure Visual score for the characterization of frontal WM lesions on FLAIR images
(A) Grade A: minor fluid-attenuated inversion recovery (FLAIR) hyperintensities, ,4 mm thick, limited to the periventricular
area, no extension into the deep and subcortical white matter (WM). Grade B: moderate FLAIR hyperintensities, ,6 mm
thick, affecting the periventricular and deep WM, no extension into the subcortical WM. Grade C: marked FLAIR hyper-
intensities, .6 mm thick, affecting periventricular, deep, and subcortical WM. (B) Frontal WM lesions were significantly
different between groups on the left side (p , 0.0001, Kruskal-Wallis test) and on the right side (p 5 0.007, Kruskal-Wallis
test). Dunn post hoc tests showed statistically significant differences between the GRN group and controls and between
the GRN group and the C9ORF72 group for the left and right side.
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